Chong Kun Dang Corporation

Seung Kee Moon

Jung Woo Kim

Hyoung Sik Chun

Soon Kil Ahn

Chung Il Hong

Nam Song Choi

Sang Joon Lee

Ryung Kee Hong

Hong Woo Lee

Jong Gwan Kim

Hung Bae Chang

Hyeog Jin Son

Cheol Kyu Han

Chung Hong, Ii

Nam Hyun Lyu

The present invention relates to Streptomyces sp. producing tautomycetin which possesses an immunosuppressive or antibacterial activities, a process for preparing tautomycetin from the said microorganism, and an immunosuppressant or immunosuppressive pharmaceutical composition comprising tautomycetin as an active ingredient which suppresses interleukin-2 production, CD69 and interleukin-2 receptor(IL-2R) expression on the cell surface, and graft rejection in the organ transplantation. The present inventors isolated a soil microorganism which produces a substance possessing antibiotic and immunosuppressive activities, and identified the said microorganism and substance as a novel Streptomyces sp. and tautomycetin, respectively. Further, the present inventors developed a method of manufacturing the tautomycetin in a large scale from the culture of the said microorganism and discovered that tautomycetin suppresses mouse mixed lymphocyte reaction(MLR) and the expression of IL-2 based on a series of experiments employing cell line transfected with a recombinant gene.

Streptomyces sp producing tautomycetin and immunosuppressant comprising tautomycetin as active ingredient

Compounds useful as angiogenesis inhibiting agents and processes for their preparation are disclosed. In one embodiment, the compounds of the invention are represented by Formula 1: ##STR1## Also disclosed is a pharmaceutical composition for inhibiting angiogenesis in a mammal, said composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof, as an active ingredient.

Fumagillol derivatives and processes for preparing the same

5-demethoxyfumagillol derivatives and processes for preparing the same

Growing community of inventors

Seoul, South Korea

Seung Kee Moon